SCHEMBL2072755

SCHEMBL2072755

COCCc1nc(-c2ccc(F)cc2)sc1C(=O)OC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 2/20 0.52
IKBKB O14920 1/20 0.46
ALDH1A1 P00352 3/20 0.45
KDM4E B2RXH2 2/20 0.45
GAA P10253 2/20 0.45
ALOX15 P16050 1/20 0.45
HSD17B10 Q99714 1/20 0.45
LMNA P02545 4/20 0.43
PPARA Q07869 1/20 0.43
MAPT P10636 7/20 0.42
TP53 P04637 2/20 0.42
PTPN11 Q06124 1/20 0.42
RAB9A P51151 3/20 0.41
NPC1 O15118 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
CASP3 P42574 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2075214 0.87 PTPN11 (0.55) TRPM8ALDH1A1KDM4EGAALMNA
SCHEMBL2076554 0.87 TRPM8 (0.64) TRPM8ALDH1A1KDM4EGAAHSD17B10
SCHEMBL2075773 0.86 NPC1 (0.57) TRPM8ALDH1A1KDM4EGAAPPARA
SCHEMBL2073937 0.78 TRPM8 (0.56) TRPM8ALDH1A1KDM4EALOX15HSD17B10
SCHEMBL12154273 0.78 TRPM8 (0.52) TRPM8ALDH1A1KDM4EGAALMNA
SCHEMBL2577814 0.77 PTPN11 (0.55) TRPM8ALDH1A1KDM4EGAALMNA
SCHEMBL976360 0.75 PTGS2 (0.58) TRPM8IKBKBALDH1A1KDM4EGAA
SCHEMBL12922064 0.75 TRPM8 (0.53) TRPM8IKBKBALDH1A1KDM4EGAA
SCHEMBL1553829 0.75 MAPT (0.56) TRPM8ALDH1A1KDM4EGAAPPARA
SCHEMBL6336484 0.75 TRPM8 (0.66) TRPM8ALDH1A1GAALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902356-B2 Thiazolopyridinone derivates as MCH receptor antagonists ELI LILLY AND COMPANY (US) 2011-03-08 US disclosed
US-7902356-B2 Thiazolopyridinone derivates as MCH receptor antagonists ELI LILLY AND COMPANY (US) 2011-03-08 US disclosed
US-7902356-B2 Thiazolopyridinone derivates as MCH receptor antagonists ELI LILLY AND COMPANY (US) 2011-03-08 US disclosed
EP-1828207-B1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2009-10-28 EP disclosed
US-20090233919-A1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY 2009-09-17 US disclosed
US-20090233919-A1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY 2009-09-17 US disclosed
US-20090233919-A1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233919-A1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS MCHR1, MCHR2, MC1R TRPM8 716/4885IKBKB 4037/4885ALDH1A1 668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.